Compare Cytokinetics Inc (CYTK) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs New York Times Co — how do they compare? Cytokinetics Inc trades at $62.52 (market cap $8.62B), while New York Times Co trades at $66.35 (market cap $10.74B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and New York Times Co for 81 Days on average.
| CYTK | NYT | |
|---|---|---|
Market Cap | $8.62B | $10.74B |
Volume | 2,594,626 | 2,096,352 |
Sector | Health | Media |
52-Week High | $87.26 | $85.86 |
52-Week Low | $54.76 | $54.66 |
Typical Hold Time | 19 Days | 81 Days |
Enterprise Value | $8.72B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
The New York Times Company (NYT) trades at $64.90, up 1.3% with a bearish technical signal despite strong fundamental performance. Recent earnings beats and consistent revenue growth to $2.82 billion in 2025 highlight operational strength, though a shareholder lawsuit and AI copyright disputes present headwinds. Analyst consensus is mixed with a $84 price target suggesting 29% upside from current levels.
The stock offers value through earnings growth and dividend yield, but faces sentiment pressure from legal challenges and technical indicators. Key risks include litigation outcomes and competitive pressures in digital media, while institutional ownership trends and positive cash flow generation support the investment case for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
